Check Cap Ltd is primarily active in the healthcare industry, specifically in the field of medical diagnostics.

The main competitors of Check Cap Ltd in the market include companies such as Exact Sciences Corporation, Cerner Corporation, and Medtronic plc.

Check Cap Ltd is a pioneering medical technology company founded in 2004. The company focuses on the development of innovative capsule-based solutions for the medical imaging industry. Check Cap Ltd specializes in developing the C-Scan® system, a patient-friendly device designed to detect colorectal polyps and other gastrointestinal abnormalities. With cutting-edge imaging technology and a commitment to improving patient care, Check Cap Ltd has become a leading player in the medical imaging industry. Known for its dedication to innovation and its focus on improving diagnostic procedures, Check Cap Ltd continues to make significant advancements in the field of gastrointestinal imaging.

Check Cap Ltd has achieved several significant milestones in its journey. Some notable achievements include the successful completion of clinical trials for its C-Scan system, which is a revolutionary ingestible capsule for colorectal cancer screening. The company has also obtained CE Mark approval for the C-Scan system, allowing it to be marketed and sold in Europe. In addition, Check Cap Ltd has entered into partnerships and collaborations with renowned healthcare institutions and industry leaders, further enhancing its position in the market. These milestones highlight Check Cap Ltd's commitment to developing innovative solutions for early detection and prevention of colorectal cancer.

Check Cap Ltd is primarily present in Israel, the United States, and Europe.

Check Cap Ltd is committed to upholding strong values and a clear corporate philosophy. As a company specializing in medical diagnostics, Check Cap prioritizes integrity, innovation, and excellence in its operations. By developing cutting-edge technologies, Check Cap aims to revolutionize the field of screening and early detection of colorectal cancer. The company's core philosophy revolves around patient care, providing non-invasive solutions for effective diagnosis. Check Cap Ltd strives to foster an environment of trust, transparency, and social responsibility, driving its commitment to improving healthcare outcomes and enhancing patients' lives.

6 analysts currently rate the Check Cap stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Check Cap to generate revenue of 76,27 Miljoen USD and earnings per share of -2,22 USD.

Check Cap Koersdoelstellingen analisten 2026

Converted at the current exchange rate, the Check Cap share trades at 6,88 EUR (8,04 USD).

The Check Cap share (MBAI) is listed on 3 stock exchanges, including: NASDAQ (CHEK), Frankfurt (7CC.F), München (7CC.MU).

Check Cap Ltd is a research-based medical technology company based in Israel. It develops products for the prevention, diagnosis, and monitoring of gastroenterological diseases, with its core product being the C-Scan®. The C-Scan® is a non-invasive, capsule-based technology that allows for the scanning of the entire digestive tract to detect potential tumors or other abnormalities early on. It offers an alternative to traditional colonoscopies and improves diagnostic accuracy. The C-Scan® is easy to use, painless, and requires no prior preparation or cleaning of the colon. Check Cap also conducts clinical studies to develop and test medications for gastroenterological diseases and works on new technologies for better visualization of the digestive tract. Its business model combines research and development, clinical studies, product development, and partnerships with other companies and institutions. With its innovative technology, Check Cap has the potential to change the way gastroenterological diseases are diagnosed, treated, and monitored.

De verwachte omzet van Check Cap bedraagt 76,27 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.

De verwachte winst van Check Cap bedraagt -15,60 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.

De koers-winstverhouding (P/E) van Check Cap bedraagt momenteel -3,62. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Check Cap-aandeel in te schatten.

De koers-omzetverhouding (P/S) van Check Cap bedraagt momenteel 0,74. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Check Cap-aandeel.

De Eulerpool Kwaliteitsscore voor Check Cap is 2/10.

De ISIN van Check Cap is IL0011336851. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.

De WKN van Check Cap is A14QUF. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.

Het tickersymbool van Check Cap is MBAI. Onder dit beurstickersymbool wordt het Check Cap-aandeel op de beurs verhandeld.

Check Cap betaalde de afgelopen 0 jaar elk jaar dividend.

Check Cap wordt toegewezen aan de sector 'Gezondheid'.

De dividenden van Check Cap worden in USD uitgekeerd.